INSIGHTS ON CLINICAL TRIAL PARTNERING

• Navigating Autoimmune Disease A Playbook For Cell And Gene Therapies

  By integrating site readiness, patient engagement, and data-driven decision-making, the cell and gene therapies (CAGT) field is advancing toward therapies that not only control disease but transform lives.

• The State Of eSource Adoption In Clinical Trials

  Learn how eSource-ready sites are improving trial efficiency, reducing site burden, and becoming essential to modern clinical trial execution.

• Redefining Site Feasibility

  Site feasibility is becoming a major source of startup delays as early requests, pre‑award outreach, and unclear communication create inaccurate projections and wasted effort.

•  Life Sciences Meetings Need More Than Logistics

  Life sciences meetings often extend beyond investigators’ meetings. Strong planning helps teams support clinical, commercial, governance, and internal programs without adding pressure to the host team.

• Evidence Of An Industry's Readiness To Collaborate

  11/13/2024

  The effort to build a single home for sites to access their trial systems has demonstrated that the industry is ready to forego competitive discourse to deliver benefits to sites and patients.

• RTSM Software Isn't One-Size-Fits-All, Especially For Small Biotechs

  5/13/2026

  Smaller biotech companies often have very different clinical trial needs than large pharmaceutical organizations, and that includes RTSM.

• Building A Scalable Oncology Engine In A Dynamic Market

  6/3/2026

  Learn how a top-10 global pharmaceutical company partnered with Medable to rapidly scale the number of oncology trials it could concurrently conduct.

• Optimizing Clinical Supply Flexibility With Demand-Led Strategies

  3/24/2026

  Explore demand-led supply strategies for clinical trials. Compare traditional vs. DLS models and learn when pack-to-order, pack-to-stock, or hybrid approaches optimize supply flexibility.

• Dedicated Community Oncology Sites

  7/29/2026

  Rapid activation, strong referral partnerships, diverse patient access, and specialized immunotherapy infrastructure are reshaping oncology research.